Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001144204-11-065145
Filing Date
2011-11-15
Accepted
2011-11-15 16:45:50
Documents
11
Period of Report
2011-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q v240370_10q.htm 10-Q 496152
2 EXHIBIT 31.1 v240370_ex31-1.htm EX-31.1 12293
3 EXHIBIT 31.2 v240370_ex31-2.htm EX-31.2 12384
4 EXHIBIT 32.1 v240370_ex32-1.htm EX-32.1 7065
5 EXHIBIT 32.2 v240370_ex32-2.htm EX-32.2 7580
  Complete submission text file 0001144204-11-065145.txt   1729394

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT tglp-20110930.xml EX-101.INS 175725
7 XBRL TAXONOMY EXTENSION SCHEMA tglp-20110930.xsd EX-101.SCH 13302
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tglp-20110930_cal.xml EX-101.CAL 31681
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tglp-20110930_def.xml EX-101.DEF 75449
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE tglp-20110930_lab.xml EX-101.LAB 76468
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tglp-20110930_pre.xml EX-101.PRE 82444
Mailing Address 125 MAIDEN LANE, SUITE 309 NEW YORK NY 10038
Business Address 125 MAIDEN LANE, SUITE 309 NEW YORK NY 10038 212-797-9877
Tongli Pharmaceuticals (USA), Inc. (Filer) CIK: 0001052284 (see all company filings)

EIN.: 841090791 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-52954 | Film No.: 111207705
SIC: 2834 Pharmaceutical Preparations